# Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia

> **NCT00401739** · PHASE1 · COMPLETED · sponsor: **CSL Limited** · enrollment: 40 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** CSL360

## Key facts

- **NCT ID:** NCT00401739
- **Lead sponsor:** CSL Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2009-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401739, "Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia". Retrieved via MORVS 2026-09-30 from https://api.morvs.ai/clinical/NCT00401739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*